

VWD Prophylaxis Works: the Evidence You Can't Ignore


The WIL-31 study, the largest prospective, non-controlled, international, multicenter phase 3 trial, has demonstrated that prophylactic treatment of Von Willebrand Disease (VWD) with Wilate[®] can significantly reduce Annualized Bleeding Rates (ABR) across various patient demographics—children and adults, males and females, and across all types of VWD.

Octapharma Canada is pleased to announce the Canadian approval of Wilate[®] for use in prophylaxis treatment of VWD in adults and pediatric patients aged 6 and older with any type of VWD.

This document provides a summary of the study's findings related to reduction in number and severity of Annualized Bleeding Rate (ABR) in children and adolescents. For detailed report, please write to us at vwd.canada@octapharma.com

VWD is a serious challenge for paediatric populations

Difficult diagnosis



Paediatric-specific VWD bleeding phenotype such as epistaxis, bruising, and oropharyngeal bleeding is common in children without VWD¹

Severe bleeding



Following surgery, dental procedures and trauma¹

Impact on HRQoL



Bleeding symptoms result in decreased HRQoL for children and their caregivers^{2,3}

Prophylaxis in children reduces the frequency of recurrent bleeds and may also prevent joint damage^{4,5}


HRQoL: Health related quality of life.

1. Sanders YV et al. *Am J Hematol* 2015; 90:1142-8; 2. Olsson A et al. *Haemophilia* 2023; 29:1056-62; 3. de Wee EM et al. *J Thromb Haemost* 2011; 9:502-9;

4. Berntorp and Petrini P. *Blood Coagul Fibrinolysis* 2005; 16 Suppl 1:S23-6; 5. Halimeh S et al. *Thromb Haemost* 2011; 105:597-604.

For full prescribing information, please refer to the product monograph.

WIL-31: Demographics of children and adolescent population




Characteristic median (range) unless otherwise specified	Children 6–11 years old (n = 9)	Adolescents 12–16 years old (n = 6)
VWD type, n (%)		
Type 1	2 (22)	1 (17)
Type 2A	2 (22)	1 (17)
Type 3	5 (56)	4 (66)
Age, years	9 (7–11)	15 (12–16)
Height, cm	136 (118–146)	165 (151–182)
Weight, kg	28 (21–41)	67 (40–92)
Caucasian, n (%)	9 (100)	6 (100)
Blood type, n (%)		
A	7 (78)	2 (33)
B	1 (11)	1 (17)
AB	1 (11)	0 (0)
O	0 (0)	3 (50)
Family history of VWD, n (%)	4 (44)	4 (67)

Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: Prophylaxis with wilate[®] reduced ABRs in children and adolescent patients

Reduction in total and spontaneous ABR during on-demand treatment and prophylaxis




SD: standard deviation.
Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: wilate[®] prophylaxis reduced bleeding in children and adolescents


Location of bleeding sites during wilate[®] prophylaxis



* Other bleeds include cutaneous, head, hip, and toe. † Other bleeds include cutaneous and tonsil. Octapharma, data on file.


WIL-31: Prophylaxis with wilate[®] reduced the number and severity of bleeds in children and adolescent patients

Patient bleeding during prophylaxis



100% of children and adolescents experienced bleeding during on-demand treatment

Bleed severity*




*Excluding menstrual bleeds.

Octapharma, data on file.

For full prescribing information, please refer to the product monograph.

WIL-31: wilate[®] prophylaxis substantially reduced joint bleeding in children and adolescents

Reduction in total ABR between on-demand treatment and prophylaxis



Children experienced no joint bleeds during prophylaxis
Adolescents experienced substantial reductions in knee and ankle joint bleeds

Octapharma, data on file.
 For full prescribing information, please refer to the product monograph.